SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

NCT05160896 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Advanced Metastatic Colorectal Cancer

Interventions

DRUG: Raltitrexed
DRUG: Irinotecan
DRUG: Bevacizumab
DRUG: Cetuximab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University